Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
Exelixis, Inc. (Nasdaq: EXEL) announces participation in investor conferences in March with webcasts available on www.exelixis.com. Management team to present at TD Cowen 44th Annual Health Care Conference, Leerink Partners Global Biopharma Conference 2024, and Barclays 26th Annual Global Healthcare Conference.
02/27/2024 - 04:05 PM
- Presentations to be webcast on www.exelixis.com -
ALAMEDA, Calif. --(BUSINESS WIRE)--
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in March:
TD Cowen 44th Annual Health Care Conference: Exelixis is scheduled to present at 10:30 a.m. ET / 7:30 a.m. PT on Tuesday, March 5 in Boston .
Leerink Partners Global Biopharma Conference 2024: Exelixis is scheduled to present at 9:20 a.m. ET / 6:20 a.m. PT on Tuesday, March 12 in Miami .
Barclays 26th Annual Global Healthcare Conference: Exelixis is scheduled to present at 10:45 a.m. ET / 7:45 a.m. PT on Wednesday, March 13 in Miami .
To access the webcast links, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location for at least 30 days.
About Exelixis
Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com , follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.
Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227523074/en/
Investors Contact:
Varant Shirvanian
Associate Director, Investor Relations
Exelixis, Inc.
650-837-8194
vshirvanian@exelixis.com
Media Contact:
Hal Mackins
For Exelixis, Inc.
415-994-0040
hal@torchcommunications.com
Source: Exelixis, Inc.
When will Exelixis participate in the TD Cowen 44th Annual Health Care Conference?
Exelixis is scheduled to present at 10:30 a.m. ET / 7:30 a.m. PT on Tuesday, March 5 in Boston.
Where can investors access the webcast links for the presentations?
Investors can access the webcast links on www.exelixis.com on the Event Calendar page under the Investors & News heading.
Will replays of the presentations be available?
Replays will be available at the same location for at least 30 days after the presentations.
EXEL Rankings
#860 Ranked by Stock Gains
EXEL Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Health Technology, Biotechnology
About EXEL
exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.